Acutus Medical Inc. (AFIB): Price and Financial Metrics


Acutus Medical Inc. (AFIB): $1.00

-0.02 (-1.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AFIB POWR Grades


  • AFIB scores best on the Growth dimension, with a Growth rank ahead of 77.73% of US stocks.
  • The strongest trend for AFIB is in Value, which has been heading up over the past 179 days.
  • AFIB ranks lowest in Quality; there it ranks in the 0th percentile.

AFIB Stock Summary

  • Acutus Medical Inc's stock had its IPO on August 6, 2020, making it an older stock than merely 3.66% of US equities in our set.
  • In terms of volatility of its share price, AFIB is more volatile than 99.41% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AFIB comes in at -158.33% -- higher than that of only 2.08% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Acutus Medical Inc, a group of peers worth examining would be FUV, KN, CLIR, ACER, and VRCA.
  • AFIB's SEC filings can be seen here. And to visit Acutus Medical Inc's official web site, go to www.acutusmedical.com.

AFIB Valuation Summary

  • AFIB's EV/EBIT ratio is -4.3; this is 114.68% lower than that of the median Healthcare stock.
  • AFIB's price/sales ratio has moved down 130.4 over the prior 13 months.
  • Over the past 13 months, AFIB's price/sales ratio has gone down 130.4.

Below are key valuation metrics over time for AFIB.

Stock Date P/S P/B P/E EV/EBIT
AFIB 2021-08-31 31.5 5.8 -3.7 -4.3
AFIB 2021-08-30 31.9 5.9 -3.8 -4.3
AFIB 2021-08-27 32.9 6.1 -3.9 -4.4
AFIB 2021-08-26 31.9 5.9 -3.8 -4.3
AFIB 2021-08-25 32.5 6.0 -3.8 -4.4
AFIB 2021-08-24 32.4 6.0 -3.8 -4.4

AFIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AFIB has a Quality Grade of F, ranking ahead of 1.4% of graded US stocks.
  • AFIB's asset turnover comes in at 0.079 -- ranking 159th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows AFIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.079 -0.743 -0.714
2021-03-31 0.066 -0.876 -0.809
2020-12-31 0.060 -0.877 -0.878

AFIB Price Target

For more insight on analysts targets of AFIB, see our AFIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.67 Average Broker Recommendation 1.6 (Moderate Buy)

AFIB Stock Price Chart Interactive Chart >

Price chart for AFIB

AFIB Price/Volume Stats

Current price $1.00 52-week high $17.21
Prev. close $1.02 52-week low $0.48
Day low $1.00 Volume 1,226,115
Day high $1.09 Avg. volume 2,495,311
50-day MA $0.81 Dividend yield N/A
200-day MA $3.30 Market Cap 28.34M

Acutus Medical Inc. (AFIB) Company Bio


Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.


AFIB Latest News Stream


Event/Time News Detail
Loading, please wait...

AFIB Latest Social Stream


Loading social stream, please wait...

View Full AFIB Social Stream

Latest AFIB News From Around the Web

Below are the latest news stories about Acutus Medical Inc that investors may wish to consider to help them evaluate AFIB as an investment opportunity.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Acutus Medical, Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm Encourages Investors in Acutus Medical, Inc. with Losses of $100,000 to Contact the Firm

Business Wire | February 18, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acutus Medical, Inc. (AFIB) Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) common stock between May 13, 2021 and November 11, 2021, inclusive (the “Class Period”). Acutus investors have until April 18, 2022 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to participate. On Novembe

Business Wire | February 18, 2022

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acutus Medical, Inc. (AFIB) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Acutus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities la

Business Wire | February 17, 2022

EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Acutus Medical, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AFIB

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acutus Medical, Inc. (NASDAQ: AFIB) between May 13, 2021 and November 11, 2021, inclusive (the "Class…

PR Newswire | February 17, 2022

The Law Offices of Frank R. Cruz Announces Investigation of Acutus Medical, Inc. (AFIB) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB) on behalf of investors concerning the Company’s possible violations of federal securities laws.. If you are a shareholder who suffered a loss, click here to participate. On November 11, 2021, Acutus announced that it was slashing its 2021 revenue guidance from a range of $22 million to $33 million down to a range of $17 million to $17.5 mil

Business Wire | February 16, 2022

Read More 'AFIB' Stories Here

AFIB Price Returns

1-mo 44.40%
3-mo -23.08%
6-mo -70.67%
1-year -94.11%
3-year N/A
5-year N/A
YTD -70.67%
2021 -88.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.409 seconds.